Source:http://linkedlifedata.com/resource/pubmed/id/12774047
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2003-5-29
|
| pubmed:abstractText |
We investigated toxicity and efficacy of in vivo T-cell depletion with anti-thymocyte globulin (ATG) as part of an intensified myeloablative conditioning regimen followed by allogeneic stem cell transplantation in patients with advanced multiple myeloma. The conditioning regimen consisted of modified total body irradiation, busulfan and cyclophosphamide (n=15) or in the case of prior dose-limiting radiotherapy of busulfan and cyclophosphamide (n=3). The median age was 44 years (range, 29-53) and the median time from diagnosis to transplant was 12 months (range, 6-144). Grade II-IV acute graft-versus-host disease (GvHD) occurred in six patients (35%). Severe grade III/IV GvHD developed in one patient (6%). Three patients died of therapy-related causes (17%). A complete remission (CR) with negative immunofixation after allogeneic transplantation was seen in eight of the evaluable patients (53%). After a median follow-up of 41 months (range, 8-84), the estimated overall survival at 6 years for all patients is 77% (CI 95%: 58-96%). The estimated progression-free survival at 6 years for all patients is 31% (CI 95%: 2-59%) and 46% (CI 95%: 9-83%) for patients with CR. In vivo T-cell depletion with ATG resulted in a low rate of severe GvHD with low treatment-related mortality, and a substantial number of long-term survivors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:AyukFrancisF,
pubmed-author:CasperJochenJ,
pubmed-author:DerigsGünterG,
pubmed-author:EinseleHermannH,
pubmed-author:FreundMathiasM,
pubmed-author:German Study-group Multiple Myeloma (DSMM),
pubmed-author:KrögerNicolausN,
pubmed-author:KrügerWilliamW,
pubmed-author:KrüllAndreasA,
pubmed-author:RengesHelmutH,
pubmed-author:Schäfer-EckartKK,
pubmed-author:SchmitzNorbertN,
pubmed-author:WandtHannesH,
pubmed-author:WittkowskyGeorgG,
pubmed-author:WolffDanielD,
pubmed-author:ZabelinaTatjanaT,
pubmed-author:ZanderAxelA
|
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
973-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12774047-Acute Disease,
pubmed-meshheading:12774047-Adult,
pubmed-meshheading:12774047-Antilymphocyte Serum,
pubmed-meshheading:12774047-Busulfan,
pubmed-meshheading:12774047-Chronic Disease,
pubmed-meshheading:12774047-Cyclophosphamide,
pubmed-meshheading:12774047-Disease-Free Survival,
pubmed-meshheading:12774047-Female,
pubmed-meshheading:12774047-Follow-Up Studies,
pubmed-meshheading:12774047-Graft vs Host Disease,
pubmed-meshheading:12774047-Humans,
pubmed-meshheading:12774047-Immunosuppressive Agents,
pubmed-meshheading:12774047-Lymphocyte Depletion,
pubmed-meshheading:12774047-Male,
pubmed-meshheading:12774047-Middle Aged,
pubmed-meshheading:12774047-Multiple Myeloma,
pubmed-meshheading:12774047-Neoplasm Staging,
pubmed-meshheading:12774047-Survival Rate,
pubmed-meshheading:12774047-T-Lymphocytes,
pubmed-meshheading:12774047-Time Factors,
pubmed-meshheading:12774047-Transplantation, Homologous,
pubmed-meshheading:12774047-Transplantation Conditioning,
pubmed-meshheading:12774047-Whole-Body Irradiation
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
|
| pubmed:affiliation |
Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|